天津發展(00882.HK):力生製藥2021年度淨利預增1176.80%-1525.02%
格隆匯1月23日丨天津發展(00882.HK)公佈,公司間接非全資附屬力生製藥(002393.SZ)預計2021年度實現歸屬於上市公司股東的淨利潤人民幣1.10億元-1.40億元,同比增長1176.80%-1525.02%;預計2021年度實現歸屬於上市公司股東的扣除非經常性損益後的淨利潤人民幣1.06億元-1.37億元,同比增長4309.13%-5598.60%。
力生製藥業績預增原因系:1、面對新冠疫情和行業變革的影響,公司積極採取有效措施,強化預算管理和成本控制,壓縮各項可控費用支出,2021年度銷售費用和管理費用均大幅下降。受公司定期存款集中到期結息影響,2021年度資金利息收益較上年增加。2、上年度公司終止23價肺炎球菌多糖疫苗項目,對相關資產計提了大額減值準備5815萬元,受該因素影響,上年度淨利潤基數較低。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.